InterCure Ltd. (TLV:INCR)
Israel · Delayed Price · Currency is ILS · Price in ILA 244.80
-7.20 (-2.86%)
May 11, 2026, 2:21 PM IDT
InterCure Revenue
In the year 2025, InterCure had annual revenue of 270.20M ILS with 13.13% growth. InterCure had revenue of 140.19M in the half year ending December 31, 2025, a decrease of -4.59%.
Revenue
270.20M
Revenue Growth
+13.13%
P/S Ratio
0.51
Revenue / Employee
844.38K
Employees
320
Market Cap
137.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 270.20M | 31.36M | 13.13% |
| Dec 31, 2024 | 238.85M | -116.71M | -32.82% |
| Dec 31, 2023 | 355.55M | -33.13M | -8.52% |
| Dec 31, 2022 | 388.68M | 169.01M | 76.93% |
| Dec 31, 2021 | 219.68M | 154.64M | 237.78% |
| Dec 31, 2020 | 65.04M | 56.11M | 628.60% |
| Dec 31, 2019 | 8.93M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 1.40M | -4.26M | -75.30% |
| Dec 31, 2014 | 5.66M | -2.57M | -31.24% |
| Dec 31, 2013 | 8.23M | -232.94K | -2.75% |
| Dec 31, 2012 | 8.46M | -3.64M | -30.10% |
| Dec 31, 2011 | 12.10M | -1.10M | -8.36% |
| Dec 31, 2010 | 13.21M | -2.93M | -18.15% |
| Dec 31, 2009 | 16.14M | -26.80K | -0.17% |
| Dec 31, 2008 | 16.16M | -17.98M | -52.66% |
| Dec 31, 2007 | 34.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 54.78B |
| Kamada | 575.31M |
| Rekah Pharmaceutical Industry | 300.99M |
| Seach Medical Group | 157.15M |
| Together Pharma | 109.63M |
| Tikun Olam-Cannbit Pharmaceuticals | 9.10M |
| Nextage Therapeutics | 243.00K |
InterCure News
- 10 days ago - InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire
- 2 months ago - InterCure receives noncompliance notification from Nasdaq - TheFly
- 2 months ago - InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement - GlobeNewsWire
- 2 months ago - InterCure reports preliminary FY25 revenue NIS 265M - TheFly
- 2 months ago - InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million - GlobeNewsWire
- 6 months ago - InterCure, Cannasoul sign strategic investment, collaboration agreements - TheFly
- 6 months ago - InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - GlobeNewsWire
- 7 months ago - InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire